Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
1.94
+0.10 (5.43%)
Sep 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.85 - 1.94
52 week 0.17 - 2.47
Open 1.87
Vol / Avg. 145,318.00/191,255.00
Mkt cap 147.48M
P/E 16.13
Div/yield     -
EPS 0.12
Shares 73.13M
Beta 2.31
Inst. own     -
Nov 10, 2016
Q3 2016 Ceapro Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 24, 2016
Q2 2016 Ceapro Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 39.25% 46.14%
Operating margin 56.75% 30.68%
EBITD margin - 38.20%
Return on average assets 38.62% 42.09%
Return on average equity 65.41% 98.75%
Employees 12 -
CDP Score - -

Address

7824 51 Avenue
EDMONTON, AB T6E 6W2
Canada
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links

Description

Ceapro Inc. is a Canada-based growth-stage biotechnology company. The Company's primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia. Its other products and technologies are in the research and development or pre-commercial stage, which include a potential platform using its beta glucan formulations, and CeaProve, a diabetes test meal to screen pre-diabetes.

Officers and directors

Gilles R. Gagnon Chief Executive Officer, Director
Age: 61
Stacy Prefontaine Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
Ulrich Kosciessa Director
William W. Li M.D. Director
Age: 50
Donald J. Oborowsky Independent Director
John Zupancic Independent Director